Reviews/Chronic Spontaneous Urticaria Treatment/Cyclosporine in omalizumab-refractory chronic spontaneous urticaria
Immunosuppression · CSU-CYC-01 · v2
Borderline: within 4 points of the Uncertain/Doubtful boundary, so a re-grade could land either side.
Cyclosporine clearly lowers hive activity in chronic spontaneous urticaria that has not responded to antihistamines. This shows up in two placebo-controlled trials [2][3], a head-to-head trial against phototherapy [1], and several real-world patient groups [7][10][14]. But the claim is specifically about patients who have already failed omalizumab, and not one of these studies actually enrolled such patients. The one study that used both drugs gave them side by side as separate options rather than trying cyclosporine after omalizumab failed [4]. The direct idea that omalizumab non-responders do well on cyclosporine appears only in review articles the panel set aside [8][11]. So the general effect is well supported while the specific omalizumab-refractory part rests on extrapolation.
Across this corpus cyclosporine consistently reduces urticaria activity in refractory CSU. Two double-blind placebo-controlled RCTs report superiority over placebo, with a mean UAS reduction of 12.7 versus 2.3 at four weeks [2] and fewer therapeutic failures on 16-week cyclosporine than placebo [3]. A head-to-head RCT shows UAS7 falling from 27.1 to 0.28 on ciclosporin [1], and observational cohorts in adults and children report high response rates [7][10] alongside an N=3 case series [14]. However, every one of these studies enrolled antihistamine-refractory or unselected recalcitrant patients, and [4] placed cyclosporine and omalizumab as parallel third-line add-ons rather than sequentially. The contested point: The division is over population, not effect: the drug-and-outcome relationship is robustly shown, but no primary study tested omalizumab-refractory patients specifically. The improvement in [1] also reversed promptly once ciclosporin stopped, so the benefit observed is confined to active treatment.
All 17 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Chronic Spontaneous Urticaria Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
No included primary study enrolled omalizumab-refractory patients — the defining qualifier of the claim. All cyclosporine trials [1][2][3] and cohorts [7][10][14] are in antihistamine-refractory or unselected refractory CSU, so the claim rests entirely on extrapolation.
Temporal confound: [2], [3] and [14] predate routine omalizumab use, so refractoriness to omalizumab could not have been a characteristic of these populations.
Where it remains uncertain. Every primary study was in antihistamine-refractory or pre-omalizumab populations, and [4] ran cyclosporine parallel to rather than after omalizumab, so the omalizumab-refractory qualifier is unsupported by primary data.
Aleatory
Response varies between patients and relapses promptly on stopping ciclosporin [1], so individual benefit is not uniform or durable.
The load-bearing papers from a corpus of 17, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
RCT showing large UAS7 reduction in the ciclosporin arm, but relapse on stopping limits durability.
“The mean (SD) UAS7 decreased from baseline scores of 24.8 (8.2) and 27.1 (8.2) to 0.82 (1.47) and 0.28 (1.4) in group A and group B, respectively at the end of the 90-day treatment (P < 0.001).”
Panel auditInternal validity: medium · scope of inference: Antihistamine-refractory, steroid-dependent CSU patients comparing ciclosporin to NB-UVB over 90 days.Key limitations: antihistamine-refractory not omalizumab-refractory · small sample · comparator is NB-UVB not placebo
Placebo-controlled RCT evidence that cyclosporin reduces urticaria activity in antihistamine-refractory CSU.
“Mean reduction in UAS between weeks 0 and 4 was 12.7 (95% confidence interval, CI 6.6-18.8) for active and 2.3 (95% CI - 3.3-7.9) for placebo (P = 0.005).”
Panel auditInternal validity: high · scope of inference: Severe antihistamine-refractory chronic urticaria with positive autologous serum skin test, over 4 weeks.Key limitations: antihistamine-refractory, pre-omalizumab population · short randomized phase · high relapse on stopping
Second placebo-controlled RCT confirming cyclosporine efficacy in recalcitrant CIU.
“Fewer therapeutic failures occurred with 16-week CsA (n = 3) than with placebo (n = 11) and 8-week CsA (n = 8).”
Panel auditInternal validity: high · scope of inference: Severe recalcitrant chronic idiopathic urticaria on cetirizine background therapy over 16 weeks.Key limitations: antihistamine-era population, not omalizumab-refractory · variable CsA dosing · failures counted rather than UAS effect size
3 of 17 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The drug-and-outcome effect in refractory CSU is strongly evidenced, but the defining omalizumab-refractory qualifier has no supporting primary data, capping confidence in the Uncertain band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Cyclosporine in documented omalizumab failures. No primary study enrolled patients defined by omalizumab non-response, the exact population the claim names [1][2][3][7][10][14]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective trial enrolling patients with confirmed inadequate response to omalizumab and randomising cyclosporine versus placebo or continued standard care, with UAS7 as the endpoint.
Open question: Does cyclosporine reduce urticaria activity in patients with an inadequate response to omalizumab specifically? Why it is still open: No included primary study enrolled omalizumab-refractory patients; all are antihistamine-refractory or pre-omalizumab [1][2][3][7][10][14].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19